Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Chief R&D Strategy Officer | November 16, 2022 | November 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date November 16, 2022 · Filed November 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,878 |
Reported balance
After 2022-11-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-16 · Exercise / conversion · Acquired 13,767 · Balance 80,878 F1: Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 90,604 |
Reported balance
After 2022-11-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-16 · Exercise / conversion · Acquired 9,726 · Balance 90,604 |
| Common StockSEC Table I · non-derivative | Direct | 96,603 |
Reported balance
After 2022-11-16 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-11-16 · Exercise / conversion · Acquired 5,999 · Balance 96,603 |
| Common StockSEC Table I · non-derivative | Direct | 132,259 |
Reported balance
After 2022-11-16 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2022-11-16 · Exercise / conversion · Acquired 35,656 · Balance 132,259 |
| Common StockSEC Table I · non-derivative | Direct | 167,590 |
Reported balance
After 2022-11-16 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2022-11-16 · Exercise / conversion · Acquired 35,331 · Balance 167,590 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2023-09-26 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-16 · Exercise / conversion · Disposed 13,767 · Balance 0 F2: The stock option is vested in full. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2024-10-22 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-16 · Exercise / conversion · Disposed 9,726 · Balance 0 F2: The stock option is vested in full. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2025-03-26 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-16 · Exercise / conversion · Disposed 5,999 · Balance 0 F2: The stock option is vested in full. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2025-10-28 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-16 · Exercise / conversion · Disposed 35,656 · Balance 0 F2: The stock option is vested in full. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2026-04-29 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-16 · Exercise / conversion · Disposed 35,331 · Balance 0 F2: The stock option is vested in full. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022.
F2: The stock option is vested in full.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2017 Filed Aug 29, 2017 23:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 3,500 | $15.00 | $52,500.00 |
DisclosureSEC source: 0001209191-17-050652 · doc4.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017. Read SEC document |
| August 28, 2017 Filed Aug 29, 2017 23:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 3,500 | $4.21 | $14,735.00 |
DisclosureSEC source: 0001209191-17-050652 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 21:55 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-17-044940 · doc4.xml · derivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,725 Underlying: Common Stock · 3,500 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 21:55 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 3,500 | $12.68 | $44,380.00 |
DisclosureSEC source: 0001209191-17-044940 · doc4.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.36 to $12.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 21:55 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 3,500 | $1.89 | $6,615.00 |
DisclosureSEC source: 0001209191-17-044940 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2017. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 20:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001209191-16-145800 · doc4.xml · derivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2026-10-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the vesting commencement date of August 10, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.